Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
| DLRHX Fund | USD 27.37 0.02 0.07% |
Slightly above 61% of Delaware Healthcare's investor base is looking to short. The analysis of overall sentiment of trading Delaware Healthcare Fund mutual fund suggests that many investors are alarmed at this time. Delaware Healthcare's investing sentiment can be driven by a variety of factors including economic data, Delaware Healthcare's earnings reports, geopolitical events, and overall market trends.
Delaware |
NEW HAVEN, Conn., Nov. 25, 2024 -- Arvinas, Inc. today announced that three posters for vepdegestrant, including clinical data, will be presented at the 2024 San Antonio Breast Cancer Symposium , being held December 10-13, 2024, in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or metastatic
Read at finance.yahoo.com
 |
Delaware Healthcare Fundamental Analysis
We analyze Delaware Healthcare's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Delaware Healthcare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Delaware Healthcare based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Delaware Healthcare is currently under evaluation in net asset among similar funds. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Delaware Healthcare Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Delaware Healthcare mutual fund to make a market-neutral strategy. Peer analysis of Delaware Healthcare could also be used in its relative valuation, which is a method of valuing Delaware Healthcare by comparing valuation metrics with similar companies.
Peers
Delaware Healthcare Related Equities
| OCLGX | Optimum Large | 0.78 | ||||
| OCIEX | Optimum International | 0.63 | ||||
| WASAX | Ivy Asset | 0.52 | ||||
| OCFIX | Optimum Fixed | 0.34 | ||||
| IMAAX | Ivy Apollo | 0.31 | ||||
| WSGAX | Ivy Small | 0.28 | ||||
| OCLVX | Optimum Large | 0.24 | ||||
| OASGX | Optimum Small-mid | 0.16 | ||||
| OASVX | Optimum Small-mid | 0.13 | ||||
| OCSGX | Optimum Small-mid | 0.13 |
Other Information on Investing in Delaware Mutual Fund
Delaware Healthcare financial ratios help investors to determine whether Delaware Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Delaware with respect to the benefits of owning Delaware Healthcare security.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |